Surgery combined with Target-reduction intensity-modulated radiotherapy
SYSUCC-CMY-20240221
Unknown other active
Quick answer
Surgery combined with Target-reduction intensity-modulated radiotherapy for Nasopharyngeal Carcinoma is a Unknown program (other) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- China SXT Pharmaceuticals
- Indication
- Nasopharyngeal Carcinoma
- Phase
- Unknown
- Modality
- other
- Status
- active